Who has been buying Samil Pharmaceutical stock?

7 distinct insiders have filed 18 disclosed insider purchases in Samil Pharmaceutical (000520), most recently on 2026-06-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Samil Pharmaceutical have?

Samil Pharmaceutical has 18 buy-side and 0 sell-side disclosures on record, covering ₩1.4B ($964K) in total reported value, spanning 2023-03-27 to 2026-06-30.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Samil Pharmaceutical 000520

Company

삼일제약Samil Pharmaceutical

Insiders

Buys

Total Value

₩1.4B ($964K)

Avg Return

+1.08%

Last Filing

2026-06-30

Samil Pharmaceutical (000520) has 18 disclosed insider purchases and 0 disclosed disposals on record, filed by 7 distinct insiders. Together those filings cover ₩1.4B ($964K) in reported transaction value. The earliest filing StockDrifts holds for Samil Pharmaceutical is dated 2023-03-27; the most recent is 2026-06-30. Across these filings the average return since disclosure is +1.08%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-06-30	BUY	Market Buy	유담향 Yudamhyang	Managing Director	1.0K	₩6,600	+3.6%	₩7M ($5K)
2026-06-10	BUY	Market Buy	차경열 Cha Kyung-yeol	Managing Director	2.0K	₩7,010	+7.3%	₩14M ($10K)
2026-06-05	BUY	Market Buy	김영대 Youngdae Kim	Managing Director	1.0K	₩7,150	+0.0%	₩7M ($5K)
2026-06-01	BUY	Market Buy	한병익 Byungik Han	vice president	1.0K	₩7,260	-2.3%	₩7M ($5K)
2026-06-01	BUY	Market Buy	유담향 Yudamhyang	Managing Director	1.0K	₩7,260	-2.3%	₩7M ($5K)
2026-05-22	BUY	Market Buy	허승범 Seungbeom Heo	CEO Chairman	10.0K	₩7,910	-4.0%	₩79M ($55K)
2026-04-30	BUY	수증	허승범 Seungbeom Heo	CEO Chairman	200.0K	₩8,890	+1.2%	₩1.8B ($1.2M)
2026-03-27	BUY	Market Buy	허승범 Seungbeom Heo	CEO Chairman	5.2K	₩10,020	-2.3%	₩52M ($36K)
2026-01-12	BUY	Market Buy	신유석 Shin Yu-seok	president	2.3K	₩9,480	+21.3%	₩22M ($15K)
2025-10-27	BUY	Market Buy	허승범 Seungbeom Heo	CEO Chairman	10.6K	₩9,730	+18.2%	₩103M ($72K)
2025-05-16	BUY	Market Buy	허준범 Junbeom Heo	Managing Director	599	₩12,140	-5.3%	₩7M ($5K)
2025-05-15	BUY	Market Buy	허준범 Junbeom Heo	Managing Director	1.2K	₩12,810	-10.2%	₩15M ($11K)
2025-05-14	BUY	Market Buy	허준범 Junbeom Heo	Managing Director	1.2K	₩12,550	-8.4%	₩15M ($10K)
2025-04-10	BUY	Market Buy	허승범 Seungbeom Heo	CEO Chairman	18.1K	₩10,950	+5.0%	₩198M ($138K)
2025-03-28	BUY	Market Buy	허준범 Junbeom Heo	Managing Director	772	₩11,350	+1.3%	₩9M ($6K)
2025-03-04	BUY	Market Buy	허승범 Seungbeom Heo	CEO Chairman	12.2K	₩12,500	-8.0%	₩153M ($106K)
2025-02-26	BUY	Market Buy	허승범 Seungbeom Heo	CEO Chairman	40.2K	₩12,640	-9.0%	₩508M ($353K)
2024-12-19	BUY	Market Buy	허승범 Seungbeom Heo	CEO Chairman	5.0K	₩13,100	-12.2%	₩66M ($45K)
2024-02-22	BUY	Market Buy	허승범 Seungbeom Heo	CEO Chairman	13.0K	₩9,070	+26.8%	₩118M ($82K)
2023-03-27	BUY	무상신주취득	허승범 Seungbeom Heo	CEO Chairman	5	₩7,060	+62.9%	₩35K ($25)

Frequently asked questions

Who has been buying Samil Pharmaceutical stock?: 7 distinct insiders have filed 18 disclosed insider purchases in Samil Pharmaceutical (000520), most recently on 2026-06-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Samil Pharmaceutical have?: Samil Pharmaceutical has 18 buy-side and 0 sell-side disclosures on record, covering ₩1.4B ($964K) in total reported value, spanning 2023-03-27 to 2026-06-30.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.